Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsing remitting Multiple Sclerosis~* Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5.~Exclusion Criteria:~* Patients with MS other than relapsing remitting MS~* Patients with a history of chronic disease of the immune system other than MS, which requires systemic immunosuppressive treatment, or a known immunodeficiency syndrome.~* Patients who have been treated with:~  * systemic corticosteroids or immunoglobulins within 1 month prior to baseline;~ * immunosuppressive medications within 3 months prior to baseline;~ * monoclonal antibodies within 3 months prior to baseline;~ * cladribine, mitoxantrone or alemtuzumab at any time.~* Uncontrolled diabetes mellitus at screening~* Diagnosis of macular edema during Screening Phase~* Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.~* Patients who have received total lymphoid irradiation or bone marrow transplantation.~* Patients with certain cardiovascular conditions and/or findings in the screening ECG~* Patients with certain liver conditions~* Pregnant confirmed by a positive pregnancy test t or nursing (lactating) women~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (Type: EXPERIMENTAL): Open-label fingolimod 0.5 mg, taken orally once daily for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).